scientific goals of the project), and to ensure the recruitment and retention of human subjects.

12. Human Subjects—The quality of procedures for the protection of human subjects, and plans for documenting all procedures for compliance with applicable published regulations.

The secondary review will be conducted by a panel of Senior Federal Officials based on the ranked proposals to assure maximal impact and balance of proposed research. The factors to be considered will include:

1. The results of the primary review including the proposal's priority score as the primary factor in the selection process.

2. The match between the proposal and the program announcement and programmatic interests.

3. The relevance and balance of proposed research relative to CDC programs and priorities.

4. The significance of the proposed activities in relation to the priorities and objectives stated in ''Health People 2000''.

5. Geographic balance and budgetary considerations.

I. Other Requirements

Technical Reporting Requirements

Provide CDC with an original plus two copies of

1. Annual progress reports,

2. Financial status report, no more that 90 days after the end of the budget period, and

3. Final financial report and performance report, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist listed in Section K ''Where to Obtain Additional Information'.

The following additional requirements are applicable to this program. For a complete description of each, see Addendum I in the application package.

AR–1—Human Subjects Requirements
AR–2—Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
AR–3—Public Health System Reporting Requirements
AR–10—Smoke-Free Workplace Requirements
AR–11—Healthy People 2000
AR–12—Lobbying Restrictions

J. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under sections 301 and 317 [42U.S.C.241 and 247b] of the Public Health Service Act, as amended. The catalog of Federal Domestic Assistance number is 93.283.

K. Where To Obtain Additional Information

This and other CDC announcements may be downloaded through the CDC homepage on the Internet at http://www.cdc.gov. Please refer to Program Announcement Number 99117 when requesting information. To receive additional written information and to request an application kit, call 1–888-GRANTS4 (1–888–472–6874). You will be asked to leave your name and address and will be instructed to identify the Announcement number of interest. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from:

Mattie Jackson, Grant Management Specialist, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, Georgia 30341–4146, Telephone: (770) 488–2718, Internet address: mij3@cdc.gov

For program technical assistance contact: Marta Gwinn, M.D., M.P.H., Office of Genetics and Disease Prevention, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE, Mailstop K–28, Atlanta, Georgia 30341–3724, telephone (770) 488–3235, Internet address: mlg1@cdc.gov

Dated: April 28, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–11097 Filed 5–3–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Radiation Studies and Research

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Grants for Radiation Studies and Research, in response to Program Announcement 99020.

Times and Dates: 8 a.m.—9 a.m., May 19, 1999 (Open); 9 a.m.—6 p.m., May 19, 1999 (Closed); 8 a.m.—5 p.m., May 20, 1999 (Closed).

Place: Centers for Disease Control and Prevention, Chamblee Campus, Building 101, (Room 1301B on May 19; Room 3002 on May 20), 4770 Buford Highway, NE, Atlanta, GA.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 99020.

Contact Person For More Information: C.M. Wood, CDC, NCEH, Chamblee Campus, Building 101, 4770 Buford Highway, NE, Atlanta, GA., phone 770/488–7642.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 28, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 99–11096 Filed 5–3–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Assessment of Preclinical Reproductive Toxicity Data; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting to discuss an approach for the integrative assessment of preclinical reproductive toxicity findings and other information for pharmaceuticals. The purpose of the meeting is to provide information on the agency's approach, using several pharmaceutical data sets, and to invite members of the public to provide comments on the utility of the approach. The agency intends to consider feedback from the meeting in the development of guidance for integrative assessments of pharmaceutical reproductive risk.

DATES: The public meeting will be held on June 24, 1999, from 9 a.m. to 4 p.m.